Yes, Standard BioTools entered into a definitive merger agreement to combine with Treeline Biosciences in an all-stock transaction. Under the terms of the agreement, the combined enterprise will operate under the name Treeline Biosciences and trade on the Nasdaq stock exchange, creating a heavily capitalized oncology-focused biopharmaceutical platform. The transaction adds substantial net cash to the combined balance sheet to support an extensive pipeline of small molecule inhibitors, protein degraders, and targeted therapies through clinical trials.